LDH and Brucellosis
LDH is not a reliable standalone marker to diagnose or monitor brucellosis; use brucella-specific microbiology/serology and organ-specific tests instead. 1
Why LDH should not guide diagnosis/monitoring of brucellosis
- Non-specificity:
- Authoritative oncology guidelines emphasize LDH rises with “almost anything” causing cell injury or hemolysis; its only proven utility there is prognostic—not diagnostic—underscoring its lack of disease specificity 1. This general principle applies to infections like brucellosis.
- Misapplied evidence:
- High-quality cardiac MCS guidelines identify LDH as specific for LVAD pump thrombosis (cutoff >2.5× ULN), a completely different context; these data do not translate to brucellosis and illustrate LDH’s context dependence 2.
- Brucellosis-specific data:
- Recent hospital cohort: in confirmed male brucellosis, higher LDH associated with blood-culture positivity, but LDH was only an adjunct predictor alongside SAT, PCT, ESR; it was not suitable as a diagnostic or monitoring marker on its own 3.
- Neurobrucellosis study: CSF LDH was higher in Brucella meningitis and contributed to a multiparameter model (AUC 0.869 for CSF LDH; 0.971 combined with CSF glucose/chloride), supporting use only as part of a CSF panel for suspected neurobrucellosis—not systemic disease diagnosis or routine monitoring 4.
Practical algorithm (prioritizing morbidity, mortality, and QOL)
- Suspected systemic brucellosis:
- Diagnose with: blood culture (multiple sets), Brucella serology (e.g., SAT), and/or PCR when available; do not use LDH to make or refute the diagnosis 3.
- Monitor response/toxicity with: clinical defervescence, symptom resolution (arthralgia, sweats), inflammatory markers (ESR/CRP), liver enzymes for drug toxicity; do not track LDH routinely.
- Suspected neurobrucellosis:
- Perform LP if focal deficits, meningitic signs, or persistent headache.
- Use CSF panel: protein (↑), glucose (↓), chloride (↓), cell count, CSF culture/PCR; CSF LDH may add diagnostic support only when combined with CSF glucose and chloride, but should not replace microbiologic confirmation or drive therapy alone 4.
- When an elevated LDH is found incidentally:
- Consider alternative causes (hemolysis, liver/muscle injury, malignancy) given LDH’s extreme non-specificity per guideline consensus 1; do not attribute to brucellosis without appropriate Brucella testing.
Pitfalls and how to avoid them
- Pitfall: Treating or “monitoring” brucellosis based on LDH fluctuations.
- Avoid: Base decisions on cultures/serology and clinical course; use organ-specific tests for complications.
- Pitfall: Extrapolating LDH cutoffs from other fields (e.g., LVAD thrombosis) to infection.
- Avoid: Recognize context-specific validity; those thresholds are irrelevant to brucellosis 2.
- Pitfall: Overinterpreting CSF LDH alone in CNS disease.
- Avoid: Interpret CSF LDH only alongside CSF glucose, chloride, protein, and microbiology, as combined models outperform single markers and better protect QOL by reducing misdiagnosis and delays 4.
Bottom line for clinical practice
- Do not order or follow LDH to diagnose or track brucellosis.
- Use LDH only as:
- A nonspecific illness-severity adjunct in already confirmed cases (e.g., higher LDH may correlate with bacteremia risk and prompt aggressive culture sampling) 3.
- A supplementary CSF marker in suspected neurobrucellosis, interpreted within a full CSF and microbiologic workup to minimize morbidity from missed CNS disease 4.